AVITA Medical, Inc. (ASX:AVH) has issued a combined 267,533 fully paid shares of common stock following the cashless exercise of previously disclosed warrants by two credit facility counterparties, according to a cleansing notice lodged under section 708A(5)(e) of the Corporations Act 2001.
Key Points
- 119,375 fully paid shares of common stock were issued to Perceptive Credit Holdings V, LP upon cashless exercise of a previously disclosed warrant.
- 148,158 fully paid shares of common stock were issued to OrbiMed Royalty & Credit Opportunities IV, LP and OrbiMed Royalty & Credit Opportunities IV Offshore, LP upon cashless exercise of a previously disclosed warrant.
- Both share issuances occurred on 11 November 2026 (United States) / 12 November 2026 (Australia).
- The new securities will be quoted on Nasdaq and may be converted into CHESS Depositary Interests (CDIs) quoted on ASX at any time by the relevant holder.
Share Issuances to Perceptive and OrbiMed
AVITA Medical issued 119,375 fully paid shares of common stock to Perceptive Credit Holdings V, LP, referred to in the filing as the Perceptive New Securities, upon that entity's cashless exercise of a previously disclosed warrant. Separately, the company issued 148,158 fully paid shares of common stock to OrbiMed Royalty & Credit Opportunities IV, LP and OrbiMed Royalty & Credit Opportunities IV Offshore, LP, referred to as the OM New Securities, upon those entities' cashless exercise of a previously disclosed warrant. Both warrants were connected to previously disclosed credit facilities entered into by the company.
Cleansing Notice and Corporations Act Compliance
The filing serves as a cleansing notice under section 708A(5)(e) of the Corporations Act 2001, as modified by Instrument 2025/180. The company disclosed that the new securities were issued without disclosure to investors under Part 6D.2 of the Corporations Act. As at the date of the notice, the company stated it had complied with the provisions of Chapter 2M of the Corporations Act as they apply to the company, and with sections 674 and 674A of the Corporations Act. The company also confirmed that, as at the date of the notice, there is no information that is excluded information within the meaning of sections 708A(7) and 708A(8) of the Corporations Act.
CDI Conversion and ASX Quotation
According to the filing, the new securities comprising both the Perceptive New Securities and the OM New Securities will be quoted on Nasdaq. The filing states that the new securities may be converted into CHESS Depositary Interests in the company quoted on ASX at any time by the relevant holder. The company disclosed that it seeks to rely on an exemption under section 708A of the Corporations Act with respect to the sale of any CDIs issued on conversion of the new securities, in the instance that such conversion occurs. The notice was authorised for release by the Chief Financial Officer of AVITA Medical, Inc.




Please wait processing your request...